健康元(600380.SH):鹽酸左沙丁胺醇霧化吸入溶液獲藥品補充申請批准通知書
格隆匯 8 月 19日丨健康元(600380.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的《藥品補充申請批准通知書》,藥品通用名稱為鹽酸左沙丁胺醇霧化吸入溶液。
本產品活性成分鹽酸左沙丁胺醇為短效β2受體激動劑,其能產生舒張支氣管平滑肌的作用,主要用於預防和治療6-11歲兒童可逆性氣道阻塞性疾病引起的支氣管痙攣,如支氣管哮喘等。
本產品是在公司已獲批的鹽酸左沙丁胺醇霧化吸入溶液(規格:3ml:0.63mg,批准文號:國藥準字H20193279)基礎上,申請新增3ml:0.31mg規格。與3ml:0.63mg規格相比,3ml:0.31mg規格更適合於6歲以上兒童哮喘患者的症狀緩解及長期控制。首次提交本品註冊申請的受理時間為2020年04月16日(受理號:CYHB2002557)。
截至公告日,鹽酸左沙丁胺醇霧化吸入溶液累計直接投入的研發費用約人民幣3578.50萬元。
鹽酸左沙丁胺醇霧化吸入溶液原研品種為Sepracor公司(後更名為“Sunovion”)的Xopenex®,該藥品3ml:0.63mg規格於1999年04月在美國上市,3ml:0.31mg規格於2002年02月上市。
根據國家藥品監督管理局藥品審評中心網站及鹹達數據庫顯示,截至公告日,國內只有公司取得該品種註冊批件,另有1家企業在審評審批中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.